Difference between revisions of "Acute myeloid leukemia, NPM1-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "][" to "] [") |
|||
Line 14: | Line 14: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
+ | |||
+ | =Guidelines= | ||
+ | =="How I Treat"== | ||
+ | *'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] | ||
=Upfront induction therapy= | =Upfront induction therapy= |
Revision as of 14:33, 10 April 2021
Section editor | |
---|---|
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO mwschoen |
Note: these are regimens tested in biomarker-specific populations for patients with NPM1-mutated AML, please see the main AML page for other regimens.
3 regimens on this page
4 variants on this page
|
Guidelines
"How I Treat"
- 2021: Falini et al. How I diagnose and treat NPM1-mutated AML
Upfront induction therapy
ICE & ATRA
back to top |
ICE & ATRA: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Schlenk et al. 2019 (AMLSG 09-09) | 2010-2017 | Phase III (C) | ICE, ATRA, GO | Did not meet primary endpoint of EFS |
To be completed
Chemotherapy
Targeted therapy
References
- AMLSG 09-09: Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. link to original article PubMed